Drug updated on 5/17/2024
Dosage Form | Injection (intramuscular; 0.5 mL) |
Drug Class | Vaccines |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).
Latest News
Summary
- Vaxzevria (COVID-19 vaccine, ChAdOx1-S [recombinant]) is indicated for the active immunization of individuals 18 years and older for the prevention of coronavirus disease 2019 (COVID-19).
- Fourteen studies were analyzed to gather information about Vaxzevria.
- Vaxzevria has been found effective and safe in the Autoimmune Rheumatic Diseases (ARD) population. However, responses could be suboptimal in individuals on certain immunomodulatory medications or with specific comorbidities.
- In African populations, Vaxzevria demonstrated wide-ranging efficacy against COVID-19 and its variants, with adverse events generally being mild to moderate, supporting the safety profile of this vaccine.
- Vaccine effectiveness, including that of Vaxzevria for preventing infections, hospitalizations, and mortality, tends to decrease over time. As a result, booster doses are recommended.
- Rare instances have linked Vaxzevria with Transverse Myelitis (TM), especially among higher age groups, where recovery was poorer compared to others.
- Vaxzevria has also been associated with Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), a condition that presents challenges in diagnosis but remains rare relative to the number of doses administered.
- Thromboembolic events post-vaccination have occurred after administering this vaccine; some cases resulted in fatality, emphasizing the need for awareness and prompt management.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Vaxzevria (COVID-19 Vaccine (ChAdOx1-S [recombinant]) Prescribing Information. | 2022 | AstraZeneca Canada Inc., Mississauga, Ontario |